Kim Catherine, Hofer Timothy P, Kerr Eve A
Division of General Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
J Gen Intern Med. 2003 Oct;18(10):854-63. doi: 10.1046/j.1525-1497.2003.20910.x.
Screening and treatment rates for dyslipidemia in populations at high risk for cardiovascular disease (CVD) are inappropriately low and rates among women may be lower than among men. We conducted a review of the literature for possible explanations of these observed gender differences and categorized the evidence in terms of a conceptual model that we describe. Factors related to physicians' attitudes and knowledge, the patient's priorities and characteristics, and the health care systems in which they interact are all likely to play important roles in determining screening rates, but are not well understood. Research and interventions that simultaneously consider the influence of patient, clinician, and health system factors, and particularly research that focuses on modifiable mechanisms, will help us understand the causes of the observed gender differences and lead to improvements in cholesterol screening and management in high-risk women. For example, patient and physician preferences for lipid and other CVD risk factor management have not been well studied, particularly in relation to other gender-specific screening issues, costs of therapy, and by degree of CVD risk; better understanding of how available health plan benefits interact with these preferences could lead to structural changes in benefits that might improve screening and treatment.
心血管疾病(CVD)高危人群中血脂异常的筛查率和治疗率低得不合理,而且女性的比率可能低于男性。我们对文献进行了综述,以寻找对这些观察到的性别差异的可能解释,并根据我们所描述的概念模型对证据进行了分类。与医生态度和知识、患者优先事项和特征以及他们相互作用的医疗保健系统相关的因素,在决定筛查率方面都可能发挥重要作用,但目前尚未得到充分理解。同时考虑患者、临床医生和卫生系统因素影响的研究和干预措施,特别是关注可改变机制的研究,将有助于我们理解观察到的性别差异的原因,并改善高危女性的胆固醇筛查和管理。例如,患者和医生对血脂及其他心血管疾病危险因素管理的偏好尚未得到充分研究,特别是与其他特定性别的筛查问题、治疗成本以及心血管疾病风险程度相关的偏好;更好地理解现有健康计划福利如何与这些偏好相互作用,可能会导致福利结构的改变,从而改善筛查和治疗。